Skip to main content
Premium Trial:

Request an Annual Quote

German Firm MTM Laboratories Raises $9.8M in Series C Round

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – German diagnostics firm MTM Laboratories announced today an additional tranche of €7 million ($9.8 million) to its Series C financing round.

The funds are an expansion of MTM's Series C from October 2009 and brings the total amount raised in the round to €46 million, the Heidelberg firm said.

Existing investors HBM BioVentures, Wellington Partners, and Gilde Healthcare Partners led the round. A consortium including National Technology Enterprises, Heidelberg Innovation, and private investors also participated.

In a statement, MTM CEO Bob Silverman said the funds will support clinical trials and commercialization efforts, and added that a large portion will go toward funding the US regulatory clinical trials for the company's CINtec Plus Cytology platform for a PMA submission.

The system is a screening and diagnostic tool that combines high sensitivity with high specificity for the detection of high-grade cervical disease in a single test. The CINtec Plus kit detects and stains for two biomarkers, cell cycle regulatory protein p16INK4a, and Ki-67.

The system was launched in Europe in March. It is CE marked and is undergoing clinical trials.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.